Drug Trial Radar · NCT04919512
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
163
Actual
Start
Jul 7, 2022
Primary completion
Feb 4, 2025
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
Conditions
- Urinary Bladder Neoplasms
Interventions
TAR-200Drug
TAR-200 will be administered.
CetrelimabBiological
Cetrelimab will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic Complete Response (pCR) RateTime frame: At Week 12
Locations
109 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Urological Associates of Southern Arizona, P.C.
Tucson, Arizona
UAMS Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas
Arkansas Urology
Little Rock, Arkansas
City of Hope
Duarte, California
Genesis Research
San Diego, California
Colorodo Urology- St. Anthony Hospital
Golden, Colorado
University of Florida Health Jacksonville
Jacksonville, Florida
Mayo Clinic
Jacksonville, Florida
Baptist Hospital of Miami
Miami, Florida
Winship Cancer Institute Emory University
Atlanta, Georgia
Mount Sinai Queens Infusion Center
Astoria, Illinois
DuPage Medical Group
Lisle, Illinois
Urology of Indiana
Indianapolis, Indiana
First Urology
Jeffersonville, Indiana
University of Louisville - James Graham Brown Cancer Center
Louisville, Kentucky
University Of Maryland Medical Center
Baltimore, Maryland
Penn Medicine - PerelmanCenter for Advanced Medicine
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Michigan Institute of Urology, PC
Troy, Michigan
University Of Minnesota
Minneapolis, Minnesota
Mayo Clinic 1
Rochester, Minnesota
Ellis Fischel Cancer Center
Columbia, Missouri
Washington University School Of Medicine - Center For Advanced Medicine (CAM)
St Louis, Missouri
David C. Pratt Cancer Center
St Louis, Missouri
Robert Wood Johnson University Hospital
New Brunswick, New Jersey
New York University Langone Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Associated Medical Professionals
Syracuse, New York
Montefiore Medical Center
The Bronx, New York
Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center
Winston-Salem, North Carolina
The Ohio State University
Columbus, Ohio
MidLantic Urology
Bala-Cynwyd, Pennsylvania
University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Urology Associates
Nashville, Tennessee
Houston Metro Urology
Houston, Texas
Urology San Antonio Research
San Antonio, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.